Belfast clinical trials company Bio-Kinetic Europe (BKE) has more than doubled its turnover and almost tripled sales to the strategically important US market in the past 12 months.
As a result of what it described as “an aggressive marketing campaign” in the US, assisted by Invest NI, the company has grown its business there to 37% of turnover from 13% a year ago.
The company has secured a series of significant contracts from global pharmaceutical corporations to trial new and existing drugs in its 40-bed clinic in Belfast city centre.
It has taken part in a number of Invest NI trade missions to the US and other markets, and been assisted by the agency’s trade advisers in Boston and San Francisco.
Marketing support has also been provided by Invest NI under the Growth Accelerator Programme, which offers fast access to funding for agreed projects in areas such as management and marketing.
In addition, the company took part in the Invest NI Preparing for Export pilot programme last year which included expert mentoring support.
BKE’s growth was announced yesterday by Moira Burke, the company’s managing director.
The news was welcomed by Tracy Meharg, managing director of Invest NI’s innovation and capability development division, during a visit to the company’s modern clinic at Great Victoria Street.